Phaseline

Companies › Surgimab

Surgimab: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SGM-101
Fluorochrome-labeled anti-CEA monoclonal antibody
CEACAM5Phase 3Colorectal Neoplasms–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03659448SGM-101Phase 3Colorectal NeoplasmsOncologyNov 2024

Targets

CEACAM5 (1)

Companies with the same targets

Chongqing Precision Biotech Beijing Biotech Merck KGaA A2 Biotherapeutics Roche Bristol-Myers Squibb LaNova Medicines Genmab Harbour BioMed (Guangzhou) Kivu Bioscience

Companies built like this

Verity Pharmaceuticals SecuraBio Fidia Farmaceutici Sumitomo Pharma Switzerland Eleison Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.